CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy

• Describe the characteristics of patients initiating each treatment (insulin or exenatide) and factors associated with treatment choice. Describe the discontinuation of oral medications following initiation of treatment with exenatide or insulin. [ Time Frame: 24 months ] [ Designated as safety issue: No ]
• Describe and compare the clinical outcomes (including change in HbA1c from baseline, % of patients achieving specific glycaemic targets, change in weight); the incidence and severity of commonly reported side-effects of these medications. [ Time Frame: 24 months ] [ Designated as safety issue: No ]
• Describe the reasons for discontinuation of insulin or exenatide. Determine which patient characteristics and other factors are associated with treatment change and describe any differences between cohorts. [ Time Frame: 24 months ] [ Designated as safety issue: No ]
• Describe and compare the health related quality of life and patient reported outcomes of patients in each cohort. Describe and compare the resource use associated with treatment for diabetes of patients in each cohort. [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Patients initiating injectable therapy for type 2 diabetes (insulin or exenatide) in usual clinical practice will be enrolled and followed up for two years in order to describe actual practice with regards to the time on initial treatment regime, whether treatment regimes are being modified in a timely manner and in response to which factors, what treatment changes are made, and clinical outcomes.

The study population will consist of patients aged 18 or above, with type 2 diabetes who, together with their physician, have decided to initiate either insulin, or exenatide for the first time for the treatment of type 2 diabetes.

• Drug: exenatide
  subcutaneous injection, 5mcg or 10mcg, twice a day
• Drug: any human insulin or analog insulin
  subcutaneous injection

• 1
  Intervention: Drug: exenatide
• 2
  Intervention: Drug: any human insulin or analog insulin

Inclusion Criteria:

• are aged 18 or above
• diagnosed with type 2 diabetes
• have had a treatment decision made within the normal course of care to initiate either insulin or exenatide for the treatment of type 2 diabetes
• have not previously been treated with either insulin or exenatide
• are not simultaneously participating in another study which includes an investigational drug or procedure at study entry
• have been fully informed and given their written consent for use of their data
• have sufficient understanding of the primary language of their country such that they will be able to complete the questionnaires.